Prolonged-Action Medications Based on Immobilized Biologically-Active Substances: AMISORB-a medicament for stomatology
Boreskov Institute of Catalysis SB RAS, Novosibirsk 630090, Russia
Development of a prolonged-action preparation exhibiting a local effect
assumes creation of a local deposit for the medication in the afflicted zone, and the
concentration of the biologically active substance should be large enough to produce the
healing effect. It is known that carbon-containing carriers, including enterosorbents, are
efficient adsorbents of biologically active and medicinal substances, namely, enzymes and
their inhibitors, aminoacids, proteins, antibiotics, and antiseptics, and they are used as
a basis for development of preparations capable of such effect.
Periodontitis, one of the most widespread diseases, leads to a
gradually increasing mobility of teeth culminating in their falling out. A medication
developed for complex treatment of inflammatory diseases of the periodon (chronic
gingivitis and periodontitis) called AMISORB is used as an application in paradontal
sulcus. Already after two to four applications, the gingiva oedema and hyperemia
disappear, and bleeding decreases strongly. Conditions favorable for rapid sanation and
simultaneous stimulation of reparative processes in the parodont tissues are thus created.
The preparation has no side effects. The period of dental recovery is shortened by two to
AMISORB is a complex medication, whose biological activity is due to
the presence of a low-molecular fibrinolysis inhibitor immobilized at the surface of a
carbon-containing enterosorbent. As a result, AMISORB is capable of a prolonged
antifibrinolytic action, as well as exhibits antibacterial activity due to adsorption of
dental pathogenic microflora, Staphylococcus aureus in particular, on the surface
of the enterosorbent. The therapeutic action of AMISORB, including a significant
shortening of the recovery period and a lengthening of the disease remission period, is a
unique characteristic of this medication and originates from its active prolonged
effect on the afflicted gum tissues, which distinduishes it favorably from the available
drugs exhibiting passive general action (vitamin complexes, herbs), as well as antiseptic
(furacilline, chlorohexidine) and irritating (rezorcine) effects.
The medication has successfully passed clinical tests at stomatological
centers. Its potential customers are pharmacies and stomatological centers.
The medication is protected by the Author's Certificate No. 162182
and an RF Patent application No. 97100376 with a priority of 14.01.1997. The owner of the
patent is the Institute of Catalysis, Siberian Branch of the Russian Academy of Sciences.